Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04365400 · ClinicalTrials.gov registry record · Phase 2
Assess Efficacy and Safety of Epeleuton in Patients With Hypertriglyceridemia and Type 2 Diabetes
A Phase 2 study, sponsored by Afimmune.
- Terminated
- Registry status
- Phase 2
- Development phase
- 233
- Enrollment target
NCT04365400 is a Phase 2 study that was terminated before completion, run by Afimmune. The registered enrollment target is 233 participants.
The verdict
NCT04365400, a Phase 2 study, was terminated before completion, sponsored by Afimmune.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 233 participants
- Enrollment target
Study Summary
To assess the efficacy and safety of orally administered Epeleuton capsules versus placebo, in the treatment of adult patients with hypertriglyceridemia and type 2 diabetes
Interventions
- DRUG Placebo
- DRUG DS102
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 233 participants |
| Start Date | 2020-10-13 |
| Est. Completion | 2022-05-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04365400
The ClinicalTrials.gov registry entry for NCT04365400 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 233 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Afimmune, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04365400 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04365400 about?
NCT04365400 is a clinical study titled "Assess Efficacy and Safety of Epeleuton in Patients With Hypertriglyceridemia and Type 2 Diabetes". To assess the efficacy and safety of orally administered Epeleuton capsules versus placebo, in the treatment of adult patients with hypertriglyceridemia and type 2 diabetes
What is the current status of trial NCT04365400?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 233 participants. The study started on 2020-10-13. Estimated completion is 2022-05-03.
What interventions are being tested in trial NCT04365400?
The interventions under investigation include: Placebo (DRUG), DS102 (DRUG).
Who is sponsoring clinical trial NCT04365400?
This trial is sponsored by Afimmune, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.